RecruitingPhase 1NCT07204340

TLN-372 in Advanced KRAS Mutant Solid Tumors

An Open-Label, Multicenter, Phase 1 Trial to Evaluate the Safety, Pharmacokinetics, and Anti-Tumor Activity of TLN-372 as a Single Agent and in Combination With Other Anti-Tumor Agents, in Patients With Advanced KRAS Mutant Solid Tumors

Sponsor

Treeline Biosciences, Inc.

Enrollment

270 participants

Start Date

Sep 29, 2025

Study Type

INTERVENTIONAL

Conditions

KRAS Mutant Solid Tumors

Summary

The primary purpose of this study is to evaluate the safety, pharmacokinetics, and anti-tumor activity of TLN-372 as a single agent and in combination with other anti-tumor agents, in patients with advanced KRAS mutant solid tumors

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called TLN-372, a drug called TLN-372 in combination with cetuximab, and others for people with kras mutant solid tumors. The study is currently recruiting participants at 11 locations. People eligible for this study include aged 18 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGTLN-372

Specified dose on specified days

DRUGTLN-372 in combination with cetuximab

Specified dose on specified days

DRUGTLN-372 in combination with pembrolizumab

Specified dose on specified days

Locations(11)

University of Alabama at Birmingham

Birmingham, Alabama, United States

Dana-Farber Cancer Institute

Boston, Massachusetts, United States

START Midwest

Grand Rapids, Michigan, United States

Washington University Medical Campus

St Louis, Missouri, United States

Memorial Sloan Kettering Cancer Center

New York, New York, United States

Sarah Cannon Research Institute

Nashville, Tennessee, United States

Peter MacCallum Cancer Centre

Melbourne, Victoria, Australia

Linear Clinical Research

Perth, Western Australia, Australia

Princess Margaret Cancer Centre

Toronto, Ontario, Canada

Hospital Universitary Vall d'Hebron

Barcelona, Spain

START Madrid_Hospital Universitario HM Sanchinarro_CIOCC

Madrid, Spain

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07204340